In the News

UbiVac to present on Dark Genome-derived Dark Matter/Proteome Cancer Immunotherapy at Spring 2025 Venture Forum

March 19, 2025

UbiVac’s Commitment to Cancer Treatment
UbiVac’s mission is the development of immunotherapies that induce broad immunity against many components of cancer, reducing the capacity of cancer to escape destruction.


Promising Phase Ib Data for UbiVac’s DPV-001 in Combination Immunotherapy for Head and Neck Squamous Cell Cancer

November 7, 2024

UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company today announced the presentation of updated results from a Phase 1b study evaluating clinical efficacy and safety of DPV-001, UbiVac’s lead investigational cancer vaccine immunotherapy, containing cancer’s dark matter, in combination with sequenced checkpoint inhibition (anti-PD-1; retifanlimab, INCMGA00012), with or without anti-GITR agonist (INCAGN01876), in adult patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) (NCT04470024) at this year’s Society for Immunotherapy of Cancer (SITC) Annual Meeting. The phase Ib study is sponsored by Providence Cancer Institute of Oregon.

• 56% objective clinical response rate and a progression-free survival of +9.3 months for patients receiving DPV-001 combination immunotherapy as first line treatment for recurrent or metastatic HNSCC
• Patients that had not responded to prior treatment with anti-PD-1 had a 33% objective clinical response rate and a progression-free survival of +6.2 months
• DPV-001 immunotherapy contains cancer’s dark matter and is designed as an off-the-shelf combination therapy option for the majority of solid cancers and for patients of all HLA backgrounds
• A T cell receptor isolated from a responding patient recognized cancers of the lung, head and neck, kidney and melanoma.


DPV-001 Vaccine Containing Cancer’s “Dark Matter” Yields 2 to >3-fold Increased Response Rate for Head and Neck Cancer

April 6, 2024

UbiVac Announces a 2 to >3-fold increase in objective clinical response rates over anti-PD-1 alone, for patients receiving DPV-001 vaccine containing cancer’s “Dark Matter” as combination immunotherapy for recurrent or metastatic HNSCC

• Responses were observed in patients that had not responded to prior treatment with anti-PD-1/L1

• DPV-001 vaccine is designed as an off-the-shelf combination therapy option for the majority of solid cancers and for patients of all HLA backgrounds